Kosan Announces Issuance of Key European Patent for Polyketide Technologies.Business Editors & Health/Medical Writers HAYWARD, Calif.--(BW HealthWire)--Nov. 9, 2001 Kosan Biosciences Incorporated (Nasdaq:KOSN) announced today that the European Patent Office issued EP Patent No. 725,778, which is exclusively licensed to Kosan by The Leland Stanford Jr. University. The claims of this patent cover methods, recombinant cells and DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. vectors for producing polyketides in heterologous heterologous /het·er·ol·o·gous/ (het?er-ol´ah-gus) 1. made up of tissue not normal to the part. 2. xenogeneic. het·er·ol·o·gous adj. 1. host cells, as well as making novel polyketides from hybrid polyketide synthase Polyketide synthases, also known as PKSs, are a family of enzymes or enzyme complexes that produce polyketides, a large class of secondary metabolites, in bacteria, fungi, plants, and animals. enzymes made using recombinant DNA technology recombinant DNA technology Recombining of DNA molecules from two different species that are inserted into a host organism to produce new genetic combinations that are of value to science, medicine, agriculture, or industry. . Polyketides are made in small amounts in microorganisms and are difficult to make or modify chemically. Kosan's technologies enable the manipulation and production of polyketides that are otherwise not possible. Using these technologies, Kosan scientists have transferred genes to better hosts to facilitate over-production and to modify, add or delete polyketide genes to make specific and predictable improvements to polyketides. "The issuance of this patent is a major milestone in Kosan's progress in protecting its proprietary technologies in the major markets worldwide," said Kevin Kaster, Vice President of Intellectual Property at Kosan. Kosan Biosciences Incorporated is a biotechnology company that has proprietary gene-engineering technologies for the manipulation and production of polyketides, a rich source of pharmaceuticals. Kosan uses its platform technologies to develop product candidates that target large pharmaceutical markets. This press release contains "forward-looking" statements, including statements relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the ability of Kosan to obtain competitive commercial benefits from its patents. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2000 and its most recent Quarterly Report on Form 10-Q Form 10-Q See 10-Q. . Kosan does not undertake any obligation to update forward-looking statements. Company Web site http://www.kosan.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion